Methods to treat cancer using cyclosporine and cyclosporine derivatives
Methods to treat certain types of cancer with cyclophilin inhibitors.
1. A method to treat a phosphatase and tensin homolog (PTEN) negative cancer in a subject in need of treatment thereof, the method comprising contacting a PTEN negative cancer in the subject with a cyclosporine, wherein the cancer is breast cancer, prostate cancer, colon cancer, glioblastoma, endometrial cancer, lung cancer, thyroid cancer, lymphomas, ovarian cancer, or a combination thereof.
2. A method to reduce growth of a phosphatase and tensin homolog (PTEN) negative cancer cell in a subject in need of treatment thereof, the method comprising:
contacting a PTEN negative cancer cell in the subject with a therapeutic amount of a cyclosporine, whereby the growth of the cancer is reduced compared to PTEN positive cancer cells, wherein the cancer is breast cancer, prostate cancer, colon cancer, glioblastoma, endometrial cancer, lung cancer, thyroid cancer, lymphomas, ovarian cancer, or a combination thereof.
3. A method to induce apoptosis of a phosphatase and tensin homolog (PTEN) negative cancer cell in a subject in need of treatment thereof, the method comprising:
contacting a PTEN negative cancer cell in the subject with a therapeutic amount of a cyclosporine, whereby apoptosis of the cancer cell is induced and the subject is treated, wherein the cancer is breast cancer, prostate cancer, colon cancer, glioblastoma, endometrial cancer, lung cancer, thyroid cancer, lymphomas, ovarian cancer, or a combination thereof.
4. A method to treat a phosphatase and tensin homolog (PTEN) negative cancer in a subject in need of treatment thereof, the method comprising:
administering to a subject diagnosed with a PTEN negative cancer a therapeutic amount of a cyclosporine, wherein the cancer is breast cancer, prostate cancer, colon cancer, glioblastoma, endometrial cancer, lung cancer, thyroid cancer, lymphomas, ovarian cancer, or a combination thereof, and whereby the cancer is treated.
5. The method of any one of claims 1 - 4 , wherein the cyclosporine is a naturally occurring cyclosporine.
6. The method of claim 5 , wherein the cyclosporine is cyclosporine A.
7. The method of any one of claims 1 - 4 , wherein the cyclosporine is a cyclosporine derivative.
8. The method of claim 7 , wherein the cyclosporine derivative is a non-immuno suppressive derivative.
9. The method of claim 7 , wherein the cyclosporine derivative is the agent of Formula I, the agent of Formula II, NIM-811, SCY-635, DEBIO-025, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, or any combination thereof.
10. The method of any one of claims 1 - 4 , wherein the cancer is a triple negative breast cancer.
11. The method of any one of claims 1 - 4 , wherein the cancer is a hormone negative prostate cancer.
12. The method of any one of claims 1 - 4 , comprising administering the cyclosporine in a combination with a therapeutic amount of a poly (ADP-ribose) polymerase (PARP) inhibitor or a deoxyribonucleic acid (DNA) cross-linking agent, or a combination thereof.
13. The method of claim 12 , wherein the DNA cross-linking agent is cisplatin, mitomycin C, cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan, bendamustine, carmustine, or any combination thereof.
14. The method of claim 12 , wherein the PARD inhibitor is olaparib.
15. The method of claim 9 , wherein the cyclosporine derivative is the agent of Formula VI.